Emre Yucel

3 Questions 7 Answers 0 Followers

Questions related from Emre Yucel

When is it a good time to consider relative risk reduction and when is it a good time for attributable risk reduction?

The above question is a prevalence question. If the prevalence of disease is high (and assuming that the disease is serious), we would consider ARR (=Risk in unexposed - Risk in treated ) versus...

07 May 2014 9,782 2 View

Is there an update on the following CIPN recommendations?

Clinicians should not offer the following agents for the prevention of CIPN to patients with cancer undergoing treatment with neurotoxic agents: Link:...

30 April 2014 2,034 2 View

Why is it that clinicians should not offer the following agents for the prevention of CIPN to patients with cancer undergoing treatment with neurotox?

ic agents: Acetyll-L-Carnitine, Amifostin, Amitriptyline, CaMg for patients receiving oxaliplatin-based chemotherapy, Diethyldithio-carbamate (DDTC), Glutathione (GSH) for patients receiving...

30 April 2014 5,444 2 View